Erythromycin in acute pharyngitis: a comparison of efficacy and patient tolerance of two twice-daily preparations.
Two hundred sixty-five adult and adolescent patients with possible streptococcal pharyngitis were treated with either erythromycin ethylsuccinate or an enteric-coated erythromycin in a twice-daily dosage schedule. In patients with group A beta-hemolytic streptococcal infection, both preparations achieved a cure rate of 93%. Patients receiving the enteric-coated erythromycin reported significantly more gastrointestinal adverse effects than did the patients receiving erythromycin ethylsuccinate.
Guthrie
R
R
Ohio State University, Columbus.
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D004334:Drug Administration Schedule; D004917:Erythromycin / Q000008:administration & dosage* / Q000009:adverse effects; D015643:Erythromycin Ethylsuccinate / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D010612:Pharyngitis / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*; D013297:Streptococcus pyogenes; D013608:Tablets, Enteric-Coated
D013608:Tablets, Enteric-Coated; D015643:Erythromycin Ethylsuccinate; D004917:Erythromycin